Rextovy utilizes the same active ingredient found in existing naloxone products, ensuring consistent efficacy for emergency treatment. This regulatory move aligns with broader federal initiatives intended to combat the ongoing substance use crisis across the United States. While the agency noted a downward trend in fatalities since the introduction of over-the-counter naloxone in 2023, drug-related deaths remain a critical public health challenge.
In section Market Quotes
Amphastar Gains FDA Nod for Over-the-Counter Opioid Overdose Spray
The Food and Drug Administration has granted approval to Amphastar Pharmaceuticals for Rextovy, a non-prescription nasal spray designed to reverse opioid overdoses. By authorizing direct consumer access at pharmacies and convenience stores, the agency aims to broaden the availability of life-saving interventions while fostering market competition to lower costs.
Data released by the FDA highlights the scale of the shift, with reported overdose deaths falling to 68,632 for the year ending in December 2025. This figure represents a significant decline from the 111,451 deaths recorded during the twelve-month period ending in August 2023. By increasing the number of accessible options for emergency responders and the general public, regulators hope to sustain this momentum in reducing preventable casualties.
Comments (0)
No comments yet. Be the first!